<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Lamotrigine in the maintenance treatment of bipolar disorder - Hashimoto, Y - 2021 | Cochrane Library</title> <meta content="Lamotrigine in the maintenance treatment of bipolar disorder - Hashimoto, Y - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013575.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Lamotrigine in the maintenance treatment of bipolar disorder - Hashimoto, Y - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013575.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013575.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Lamotrigine in the maintenance treatment of bipolar disorder" name="citation_title"/> <meta content="Yasuhiko Hashimoto" name="citation_author"/> <meta content="Kobe Gakuin University" name="citation_author_institution"/> <meta content="yhashi@pharm.kobegakuin.ac.jp" name="citation_author_email"/> <meta content="Kazumasa Kotake" name="citation_author"/> <meta content="Okayama Saiseikai General Hospital" name="citation_author_institution"/> <meta content="Norio Watanabe" name="citation_author"/> <meta content="Kyoto University School of Public Health" name="citation_author_institution"/> <meta content="Takashi Fujiwara" name="citation_author"/> <meta content="Kurashiki Central Hospital" name="citation_author_institution"/> <meta content="Shinji Sakamoto" name="citation_author"/> <meta content="Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD013575.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013575.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013575.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013575.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [therapeutic use]; *Bipolar Disorder [drug therapy]; Lamotrigine [adverse effects]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013575.pub2&amp;doi=10.1002/14651858.CD013575.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013575\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013575\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013575.pub2",title:"Lamotrigine in the maintenance treatment of bipolar disorder",firstPublishedDate:"Sep 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013575.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013575.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013575.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013575.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013575.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013575.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013575.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013575.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013575.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013575.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12187 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013575.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/appendices#CD013575-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/supinfo/CD013575StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/supinfo/CD013575StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Lamotrigine in the maintenance treatment of bipolar disorder</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#CD013575-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Yasuhiko Hashimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#CD013575-cr-0005">Kazumasa Kotake</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#CD013575-cr-0006">Norio Watanabe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#CD013575-cr-0007">Takashi Fujiwara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information#CD013575-cr-0008">Shinji Sakamoto</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information/en#CD013575-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013575.pub2">https://doi.org/10.1002/14651858.CD013575.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013575-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013575-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013575-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013575-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013575-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013575-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013575-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013575-abs-0001" lang="en"> <section id="CD013575-sec-0001"> <h3 class="title" id="CD013575-sec-0001">Background</h3> <p>Bipolar disorder is a chronic mental disorder with repetitive mania/hypomania as well as depressive episodes, which eventually results in marked impairment in overall functioning and health‐related quality of life.  A worldwide prevalence rate of 2.4% has been reported. The risk of suicide is higher in people with bipolar disorder than those with other mental disorders. Therefore, effective management of bipolar disorder in the maintenance period is warranted to minimize the risk of relapse or recurrence. Although lithium has been the standard treatment of bipolar disorder for many years, it is associated with adverse effects and teratogenicity. Lamotrigine is approved to be expected for prevention of recurrence for the maintenance treatment of bipolar disorder. In addition, lamotrigine is as effective as lithium. Therefore, we performed a systematic review to confirm the efficacy and safety of lamotrigine in the maintenance treatment of bipolar disorder. </p> </section> <section id="CD013575-sec-0002"> <h3 class="title" id="CD013575-sec-0002">Objectives</h3> <p>To assess the efficacy and tolerability of lamotrigine in the maintenance treatment of bipolar disorder. </p> </section> <section id="CD013575-sec-0003"> <h3 class="title" id="CD013575-sec-0003">Search methods</h3> <p>We searched Ovid MEDLINE, Embase, PsycINFO, the Cochrane Common Mental Disorders Group's Specialized Register (CCMDCTR) and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 21 May 2021. We also searched international trial registries and contacted experts in the field. </p> </section> <section id="CD013575-sec-0004"> <h3 class="title" id="CD013575-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials enrolling adults with bipolar disorder who were treated with lamotrigine, placebo or lithium. </p> </section> <section id="CD013575-sec-0005"> <h3 class="title" id="CD013575-sec-0005">Data collection and analysis</h3> <p>Two reviews authors independently checked the eligibility of studies and extracted data using a standardized form. Data extracted included study characteristics, participant characteristics, intervention details, settings, and outcome measures in the term of efficacy and tolerability. Study information were then entered into RevMan web. </p> </section> <section id="CD013575-sec-0006"> <h3 class="title" id="CD013575-sec-0006">Main results</h3> <p>We included 11 studies with a total of 2314 participants in this review; 1146 were randomized to lamotrigine, 869 were randomized to placebo and, 299 to lithium. </p> <p>We rated all studies as having an unclear risk of bias in at least one domain of Cochrane's tool for assessing risk of bias, with the most commonly observed weakness being selection bias (random sequence generation and allocation concealment). We judged five studies to be at a high risk of detection bias (blinding of outcome assessment). These potential biases pose as major threat to the validity of the included studies in this review. </p> <p>Outcomes of efficacy showed a possible advantage of lamotrigine over placebo. The estimated risk ratio (RR) for recurrence of manic symptom at one year as measured by the Young Mania Rating Scale (YMRS) was 0.67, (95% confidence interval (CI) 0.51 to 0.87; 3 studies, 663 participants; low‐certainty evidence) in favor of lamotrigine. The RR of clinical worsening with the need for additional psychotropic treatment (RR 0.82, 95% CI 0.70 to 0.98; 4 studies, 756 participants) based on moderate‐certainty evidence. The possible benefits of lamotrigine were also seen for the outcome of treatment withdrawal due to any reason at 6‐12 months after treatment (RR 0.88, 95% CI 0.78 to 0.99; 4 studies, 700 participants; moderate‐certainty evidence). Regarding tolerability, our analyses showed that the incidence rates of adverse effects were similar between the lamotrigine group and the placebo group (short‐term effect: RR 1.07, 95% CI 0.81 to 1.42; 5 studies, 1138 participants; very low‐certainty evidence; long‐term effect: RR 0.97, 95% CI 0.77 to 1.23; 4 studies, 756 participants; moderate‐certainty evidence). </p> <p>In the comparison between lamotrigine and lithium, efficacy was similar between groups except for recurrence of mania episode at one year. Recurrence of manic symptoms was higher in the lamotrigine group than that of the lithium group (RR 2.13, 95% CI 1.32 to 3.44; 3 studies, 602 participants; moderate‐certainty evidence). Analysis of adverse effects at 6‐12 months showed that a lower proportion of participants experienced at least one adverse effect when treated with lamotrigine compared to lithium (RR 0.70, 95% CI 0.51 to 0.96; 4 studies, 691 participants; moderate‐certainty evidence). </p> </section> <section id="CD013575-sec-0007"> <h3 class="title" id="CD013575-sec-0007">Authors' conclusions</h3> <p>Low‐ to moderate‐certainty evidence collectively suggests that lamotrigine may be superior to placebo as a treatment modality for bipolar disorder. In comparison to lithium, people with bipolar disorder seem to tolerate lamotrigine better in the long run; however, the demonstrated efficacy in the maintenance of bipolar disorder was similar between the two groups. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013575-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013575-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013575-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013575-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013575-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013575-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013575-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013575-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013575-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013575-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013575-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013575-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013575-abs-0002" lang="en"> <h3>Lamotrigine as a treatment for prevention of recurrence of bipolar disorder</h3> <p><b>Review question</b> </p> <p>To investigate the clinical effectiveness (benefits and harms) of lamotrigine for maintenance therapy of bipolar disorder in comparison with placebo, combination therapy or existing drugs (e.g. lithium, olanzapine). </p> <p><b>Background</b> </p> <p>Lamotrigine is approved for the maintenance treatment (treatment for prevention of recurrence) of bipolar disorder. It could be a viable and effective treatment strategy for the maintenance of bipolar disorder, where it demonstrated a lower risk of recurrence than placebo. In addition, it has been reported to be as effective as lithium. Therefore, we performed a systematic review to investigate the efficacy and safety of lamotrigine in the maintenance treatment (treatment for prevention of recurrence) of bipolar disorder. </p> <p><b>Key findings</b> </p> <p>The evidence is current to May 2021. We included 11 studies in this review with a total 2314 participants. 1146 participants were assigned to lamotrigine, and 1168 participants were assigned to control intervention (869 received placebo and 299 received lithium). </p> <p>Our review identified the following.</p> <p>Lamotrigine versus placebo</p> <p>Benefits: lamotrigine was found to be superior over placebo in the following outcomes.</p> <p>1) Reduced the rate of recurrence of manic symptoms </p> <p>2) Suppressed depressive symptoms</p> <p>3) Less need for additional therapeutic agents for the recurrence of all symptoms</p> <p>4) Reduction in the withdrawal rate due to any causes six months or more after the initiating of intervention </p> <p>Harms: adverse‐event profile of lamotrigine was similar to that of placebo.</p> <p>Lamotrigine versus lithium </p> <p>Benefits: lamotrigine was as effective as lithium, except for the recurrence of manic symptoms, for which the rate was higher in people who received lamotrigine than people treated with lithium. </p> <p>Harms: the rate of adverse events associated with lamotrigine was lower than that of lithium. </p> <p><b>Certainty of the evidence</b> </p> <p>We assessed the certainty of our included evidence to be very low to moderate. This is because majority of the included trials did not describe how treatment allocation was concealed. Given that we were unable to identify high‐confidence evidence the overall findings of this systematic review should be interpreted carefully. </p> <p><b>Conclusions</b> </p> <p>Lamotrigine may be superior to placebo in efficacy and may be comparable in safety. And then, lamotrigine was as effective as lithium except for its recurrence rate of mania, and was superior to lithium in terms of safety. Future studies in this field with robust methods and transparent reporting are needed to confirm our results and to fully answer our pre‐specified review question. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013575-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013575-sec-0106"></div> <h3 class="title" id="CD013575-sec-0107">Implications for practice</h3> <section id="CD013575-sec-0107"> <p>Findings from our review showed a potential superiority of lamotrigine over placebo in terms of recurrence prevention and treatment continuation. The incidence of adverse effects was similar between lamotrigine and placebo regardless of the duration of the studies. Therefore, lamotrigine is considered to be sufficiently useful in the maintenance treatment for bipolar disorder. In comparison with lithium, change in rating scale mania as well as depression, addition of therapeutic intervention for any mood episodes, treatment continuation, and recurrence of depressive episode for one year were similar in lamotrigine. Although lamotrigine worsened the recurrence of mania episode for one year, tolerability was superior to lamotrigine for lithium. These results are consistent with current guidelines for treatment of bipolar disorder (<a href="./references#CD013575-bbs2-0094" title="YathamLN , KennedySH , ParikhSV , SchafferA , BondDJ , FreyBN , et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders2018;20(2)::97-170.">Yatham 2018</a>). In the pharmacotherapy of bipolar disorder, the use of antipsychotic agents as well as mood stabilizers has been increased in recent years. However, these are primarily treatments for manic symptoms of bipolar disorder; there is no robust treatment strategy for depressive symptoms during the maintenance phase. Lithium, which has been used as standard first‐line treatment, is associated with severe adverse effects and thus prone to treatment discontinuation and non‐compliance. Furthermore, in Japan, lithium is contraindicated for pregnant and lactating women. In this review, we could not comprehensively evaluate the safety profile of lamotrigine for pregnant and lactating women due to insufficient data. Nonetheless, our findings on relapse prevention by lamotrigine suggests that it is a viable maintenance treatment option for people with bipolar disorder.  </p> </section> <h3 class="title" id="CD013575-sec-0108">Implications for research</h3> <section id="CD013575-sec-0108"> <p>The overall low‐ to moderate‐certainty evidence is indicative of the need to design and execute robust, large‐scale randomized studies of lamotrigine amongst people with bipolar disorder, with particular considerations on the methodological shortcomings in randomization method, allocation concealment and blinding of outcome assessment as identified in our review. For effective clinical decision‐making, results of our present review will contribute to an ongoing network meta‐analysis of drug treatments for people with bipolar disorder, which aims to provide a solid evidence base in regards to efficacy and safety of the wide array of drug treatment options available for bipolar disorder.  </p> <p>We initially planned to explore the efficacy and safety profile of lamotrigine (as monotherapy or in combination with other pharmacological agents) in pregnant and lactating women, and assessing the quality of life or satisfaction amongst treated individuals. However, we did not identify eligible studies involving pregnant and lactating women and none of the studies assessed quality of life or patient satisfaction. These are important knowledge gaps and their evidence is critical for effective clinical practice management, in particular to enhance treatment safety and compliance. We urge study investigators in the field to continue, and should be systematically reviewed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013575-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013575-sec-0008"></div> <div class="table" id="CD013575-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lamotrigine versus placebo for the maintenance treatment of bipolar disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine versus placebo in the maintenance treatment of bipolar disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> bipolar disorder<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (hospitalization for any episodes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Young Mania Rating Scale (YMRS) total score ≥15 for manic episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.51 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>663<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies reported that no recurrence of any episodes for one year Young Mania Rating Scale total score 15 or greater for manic episode was recorded in the lamotrigine and control groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/>(48 to 159) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥15 for depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥14 for depressive episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1606<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>438 per 1,000<br/>(340 to 536) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.70 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>756<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000<br/>(428 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (active suicidal behavior)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was measured in one study, but no numeric data were provided.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.70 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>195<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 7 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1,000<br/>(196 to 472) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.78 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>700<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 1,000<br/>(426 to 625) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects up to 12 weeks after starting treatment (short term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.81 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1138<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 9 10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1,000<br/>(208 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects 6‐12 months after initiating the intervention (long term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>756<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1,000<br/>(428 to 594) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of manic episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.66 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>574<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1,000<br/>(149 to 288) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of depressive episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.53 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>574<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1,000<br/>(225 to 374) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by the 36‐Item Short Form Health Survey</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total severity score from depression and mania symptom scores, such as HDRS and the YMRS </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0 to 0 ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Publication bias was not evaluated due to limited data. </p> <p><sup>2</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a> and <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>3</sup> Downgraded by one level. Only <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a> provided OR and 95% CI. </p> <p><sup>4</sup> Downgraded by one level for inconsistency (I<sup>2</sup>= 60%). </p> <p><sup>5</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a> had unclear to high risk of detection bias (blinding of outcome assessors). </p> <p><sup>6</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>7</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> was included with unclear risk of bias). </p> <p><sup>8</sup> Downgraded by one level. Only <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> provided OR and 95% CI. </p> <p><sup>9</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> and <a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>10</sup> Downgraded by two levels for very serious inconsistency (I<sup>2</sup>= 82%) </p> <p><sup>11</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013575-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine versus lithium for the maintenance treatment of bipolar disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine versus lithium in the maintenance treatment of bipolar disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> bipolar disorder<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> lithium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lithium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (hospitalization for any episodes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Young Mania Rating Scale (YMRS) total score ≥15 for manic episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.57<br/>(0.15 to 85.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥15 for depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥14 for depressive episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.70 to 2.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/>(44 to 179) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.92 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1,000<br/>(380 to 543) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (active suicidal behavior)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.06 to 15.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>155<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000<br/>(1 to 176) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.88 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>636<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>663 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1,000<br/>(491 to 677) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects up to 12 weeks after starting treatment (short term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects 6‐12 months after initiating the intervention (long term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.51 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>691<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1,000<br/>(164 to 294) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of manic episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/>(1.32 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>206 per 1,000<br/>(136 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of depressive episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.63 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1,000<br/>(227 to 373) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by the 36‐Item Short Form Health Survey</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total severity score from depression and mania symptom scores, such as HDRS and the YMRS </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was included). </p> <p><sup>2</sup> Downgraded by two levels due to wide CIs. </p> <p><sup>3</sup> Publication bias was not evaluated due to limited data. </p> <p><sup>4</sup> Downgraded by one level due to wide CIs. </p> <p><sup>5</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a> and <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> were judged to be at high risk of detection bias (blinding of outcome assessment). </p> <p><sup>6</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a> was included). </p> <p><sup>7</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a> were judged to be at high risk of detection bias (blinding of outcome assessment). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013575-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013575-sec-0009"></div> <section id="CD013575-sec-0010"> <h3 class="title" id="CD013575-sec-0010">Description of the condition</h3> <p>Bipolar disorder is a chronic mental disorder with repetitive cycles of mania/hypomania as well as depressive episodes, which eventually results in marked impairment in overall functioning and health‐related quality of life (<a href="./references#CD013575-bbs2-0052" title="deHertM , CorrellCU , BobesJ , Cetkovich-BakmasM , CohenD , AsaiI ,  et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry2011;10(1):52-77. [PMID: 21379357]">de Hert 2011</a>). It is described by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) tool as a type of mental health condition that leads to extreme fluctuation in a person's mood, energy, and ability to function (<a href="./references#CD013575-bbs2-0039" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association. 2013. Available from dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596.">American Psychiatric Association 2013</a>). Bipolar disorder was the 46th greatest causes of disability‐adjusted life years (DALYs) in the world, placing it ahead of Alzheimer's disease and other dementias among the 291 disorders included in the Global Burden of Disease Study 2010 (<a href="./references#CD013575-bbs2-0072" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2197-223.">Murray 2012</a>), and it has a worldwide prevalence of 2.4% (<a href="./references#CD013575-bbs2-0068" title="MerikangasKR , JinR , HeJP , KesslerRC , LeeS , SampsonNA , et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of General Psychiatry2011;68(3):241-51. [PMID: 21383262]">Merikangas 2011</a>). Bipolar disorder affects approximately 60 million people worldwide (<a href="./references#CD013575-bbs2-0092" title="World Health Organization. Mental disorders. www.who.int/news-room/fact-sheets/detail/mental-disorders (accessed 6 July 2021).">WHO 2019a</a>). The risk of suicide is higher in people with bipolar disorder than those with other mental disorders (<a href="./references#CD013575-bbs2-0075" title="NordentoftM , MortensenPB , PedersenCB . Absolute risk of suicide after first hospital contact in mental disorder. Archives of General Psychiatry2011;68(10):1058-64. [PMID: 21969462]">Nordentoft 2011</a>). The estimated rate of death by suicide was 0.2 people per year to 0.4 people per year among people with bipolar disorder (<a href="./references#CD013575-bbs2-0083" title="SondergardL , LopezAG , AndersenPK , KessingLV . Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disorders2008;10(1):87-94. [PMID: 18199245]">Sondergard 2008</a>), and one‐year recurrence rate was 26.3% (<a href="./references#CD013575-bbs2-0085" title="VazquezGH , HoltzmanJN , LolichM , KetterTA , BaldessariniRJ . Recurrence rates in bipolar disorder: systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials. European Neuropsychopharmacology2015;25(10):1501-12. [PMID: 26238969]">Vazquez 2015</a>). Therefore, in addition to treating recurrent mania/hypomania and depressive episodes, effective management of bipolar disorder after acute treatment of mood episodes using long‐term continuation therapy is warranted in order to minimize the risk of relapse or recurrence (<a href="./references#CD013575-bbs2-0049" title="CalabreseJR , GoldbergJF , KetterTA , SuppesT , FryeM , WhiteR , et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biological Psychiatry2006;59(11):1061-4.">Calabrese 2006</a>). </p> </section> <section id="CD013575-sec-0011"> <h3 class="title" id="CD013575-sec-0011">Description of the intervention</h3> <p>For many years, lithium has been the standard treatment of bipolar disorder with acute mood episodes, polarity change prevention, prophylactic treatment, and suicide prevention (<a href="./references#CD013575-bbs2-0041" title="BALANCE investigators and collaborators, GeddesJR , GoodwinGM , RendellJ , AzorinJM , CiprianiA , OstacherMJ , et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet2010;375(9712):385-95.">BALANCE investigators and collaborators 2010</a>; <a href="./references#CD013575-bbs2-0082" title="SmithLA , CorneliusV , WarnockA , BellA , YoungAH . Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders2007;9(4):394-412. [PMID: 17547586]">Smith 2007</a>; <a href="./references#CD013575-bbs2-0095" title="YildizA , VietaE , LeuchtS , BaldessariniRJ . Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology2011;36(2):375-89. [PMID: 20980991]">Yildiz 2011</a>). However, questions were raised over the potential overestimation of the effectiveness of lithium and the frequency of use of lithium for bipolar disorder is decreasing (<a href="./references#CD013575-bbs2-0044" title="BlancoC , LajeG , OlfsonM , MarcusSC , PincusHA . Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry2002;159(6):1005-10. [PMID: 12042190]">Blanco 2002</a>; <a href="./references#CD013575-bbs2-0067" title="LyallLM , PenadesN , SmithDJ . Changes in prescribing for bipolar disorder between 2009 and 2016: national-level data linkage study in Scotland. British Journal of Psychiatry2019;215:415-21.">Lyall 2019</a>). Furthermore, lithium has been associated with congenital malformations during pregnancy for the fetus (<a href="./references#CD013575-bbs2-0079" title="PoelsEM , BijmaHH , GalballyM , BerginkV . Lithium during pregnancy and after delivery: a review. International Journal of Bipolar Disorders2018;6(1):26. [PMID: 30506447]">Poels 2018</a>). It has been reported that rates of recurrence after lithium discontinuation sharply increased postpartum (<a href="./references#CD013575-bbs2-0089" title="VigueraAC , NonacsR , CohenLS , TondoL , MurrayA , BaldessariniRJ . Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. American Journal of Psychiatry2000;157(2):179-84. [PMID: 10671384]">Viguera 2000</a>). Sodium valproate and carbamazepine, both antiepileptic drugs, are effective for the management of the bipolar mania and acute symptoms (<a href="./references#CD013575-bbs2-0046" title="BowdenCL , SinghV . Valproate in bipolar disorder: 2000 onwards. Acta Psychiatrica Scandinavica2005;111(Suppl 426):13-20. [PMID: 15833096]">Bowden 2005</a>; <a href="./references#CD013575-bbs2-0058" title="GreilW , KleindienstN , ErazoN , Muller-OerlinghausenB . Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology1998;18(6):455-60. [PMID: 9864077]">Greil 1998</a>); however, they are relatively less effective against depression of maintenance phase and depression of bipolar disorder (<a href="./references#CD013575-bbs2-0073" title="NgF , HallamK , LucasN , BerkM . The role of lamotrigine in the management of bipolar disorder. Neuropsychiatric Disease and Treatment2007;3(4):463-74. [PMID: 19300575]">Ng 2007</a>). Atypical antipsychotics including olanzapine (<a href="./references#CD013575-bbs2-0042" title="BerkM , IchimL , BrookS . Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. International Clinical Psychopharmacology1999;14(6):339-43. [PMID: 10565800]">Berk 1999b</a>), quetiapine (<a href="./references#CD013575-bbs2-0048" title="CalabreseJR , Keck PE Jr, MacfaddenW , MinkwitzM , KetterTA , WeislerRH , et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry2005;162(7):1351-60. [PMID: 15994719]">Calabrese 2005</a>; <a href="./references#CD013575-bbs2-0065" title="KetterTA , JonesM , PaulssonB . Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. Journal of Affective Disorders2007;100 Suppl 1:S45-53. [PMID: 17383011]">Ketter 2007</a>), aripiprazole (<a href="./references#CD013575-bbs2-0064" title="Keck PE Jr, MarcusR , TourkodimitrisS , AliM , LiebeskindA , SahaA , et al, Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry2003;160(9):1651-8. [PMID: 12944341]">Keck 2003</a>), and risperidone (<a href="./references#CD013575-bbs2-0081" title="SegalJ , BerkM , BrookS . Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology1998;21(3):176-80. [PMID: 9617509]">Segal 1998</a>) have also demonstrated efficacy in the treatment of mania. For the new anticonvulsants such as gabapentin (<a href="./references#CD013575-bbs2-0088" title="VietaE , Manuel GoikoleaJ , Martinez-AranA , ComesM , VergerK , MasramonX , et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry2006;67(3):473-7. [PMID: 16649836]">Vieta 2006</a>), topiramate (<a href="./references#CD013575-bbs2-0078" title="PigottK , GaliziaI , VasudevK , WatsonS , GeddesJ , YoungAH . Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD003384. [DOI: 10.1002/14651858.CD003384.pub3]">Pigott 2016</a>), zonisamide (<a href="./references#CD013575-bbs2-0051" title="DauphinaisD , KnableM , RosenthalJ , PolanskiM , RosenthalN . Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacology Bulletin2011;44(1):5-17. [PMID: 22506436]">Dauphinais 2011</a>), and levetiracetam (<a href="./references#CD013575-bbs2-0063" title="KaufmanKR . Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy &amp; Behavior2004;5(6):1017-20. [PMID: 15582854]">Kaufman 2004</a>), sufficient efficacy has not been demonstrated for bipolar disorder. Thus, there remains a need to identify additional pharmacological agents with sufficient and up‐to‐date evidence to demonstrate their effectiveness in preventing and managing relapse of bipolar disorder. </p> <p>Lamotrigine is approved for the maintenance treatment of adults with bipolar disorder. Lamotrigine is indicated for use in numerous clinical guidelines as a first‐line pharmacological agent in the treatment of bipolar depression (<a href="./references#CD013575-bbs2-0074" title="NivoliAM , ColomF , MurruA , PacchiarottiI , Castro-LoliP , Gonzalez-PintoA , et al. New treatment guidelines for acute bipolar depression: a systematic review. Journal of Affective Disorders2011;129(1-3):14-26. [PMID: 20538341]">Nivoli 2011</a>). Lamotrigine is licensed by the US Food and Drug Administration (FDA) for the prevention of relapses in people with bipolar disorder. Although the evidence base regarding long‐term efficacy of lamotrigine is reasonably robust, five pivotal trials conducted in acute‐phase therapy reported relatively neutral findings and they found no statistically significant benefits (<a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a>). Previous studies found that lamotrigine could be a viable and effective treatment modality for the maintenance of bipolar disorder, where it illustrated a lower risk of recurrence than placebo (<a href="./references#CD013575-bbs2-0055" title="GeddesJR , CalabreseJR , GoodwinGM . Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry2009;194(1):4-9. [PMID: 19118318]">Geddes 2009</a>; <a href="./references#CD013575-bbs2-0069" title="MiuraT , NomaH , FurukawaTA , MitsuyasuH , TanakaS , StocktonS , et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry2014;1(5):351-9. [PMID: 26360999]">Miura 2014</a>; <a href="./references#CD013575-bbs2-0076" title="OyaK , SakumaK , EsumiS , HashimotoY , HatanoM , MatsudaY , et al. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology Reports2019;39(3):241-6. [PMID: 31026388]">Oya 2019</a>). It has also been reported to be equally effective as lithium, which is the standard treatment for bipolar disorder (<a href="./references#CD013575-bbs2-0084" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. [PMID: 18358540]">Suppes 2008b</a>). In addition, lamotrigine demonstrated a better safety profile compared to lithium in postpartum teratogenicity (<a href="./references#CD013575-bbs2-0057" title="GrahamRK , TavellaG , ParkerGB . Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?Journal of Affective Disorders2018;228:216-21. [PMID: 29274567]">Graham 2018</a>), although available evidence from a population‐based cohort study found that it was equivalent to lithium in the prevention of (hypo) manic or depressive episodes (<a href="./references#CD013575-bbs2-0091" title="WesselooR , LiuX , ClarkCT , KushnerSA , Munk-OlsenT , BerginkV . Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. Journal of Affective Disorders2017;218:394-7. [PMID: 28501739]">Wesseloo 2017</a>). It is worth highlighting that lamotrigine has been proposed as a treatment option for bipolar disorder during pregnancy among mothers who are at risk of depression. For example, <a href="./references#CD013575-bbs2-0066" title="KongL , ZhouT , WangB , GaoZ , WangC . The risks associated with the use of lamotrigine during pregnancy. International Journal of Psychiatry in Clinical Practice2018;22(1):2-5. [PMID: 28657488]">Kong 2018</a> indicated that lamotrigine could be a safe mood stabilizer for use during pregnancy based on available clinical evidence; <a href="./references#CD013575-bbs2-0086" title="VeronikiAA , CogoE , RiosP , StrausSE , FinkelsteinY , KealeyR , et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Medicine2017;15(95):1-20. [PMID: 28472982]">Veroniki 2017</a> conducted a systematic review on the safety of antiepileptic drugs in pregnancy which included 96 (n=58,461 patients) studies, most were cohort studies. The risk of congenital malformations with lamotrigine was comparable to placebo (OR, 0.96; 95% CI, 0.72–1.25). and less than with other antiepileptic drugs (ethosuximide (OR, 3.04; 95% CI, 1.23–7.07), valproate (OR, 2.93; 95% CI, 2.36–3.69), topiramate (OR, 1.90; 95% CI, 1.17–2.97), phenobarbital (OR, 1.83; 95% CI, 1.35–2.47), phenytoin (OR, 1.67; 95% CI, 1.30–2.17), carbamazepine (OR, 1.37; 95% CI, 1.10–1.71). </p> </section> <section id="CD013575-sec-0012"> <h3 class="title" id="CD013575-sec-0012">How the intervention might work</h3> <p>Lamotrigine is an antiepileptic drug belonging to the phenyltriazine class used in the treatment of epilepsy and bipolar disorder. Lamotrigine works by inhibiting voltage‐sensitive sodium channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release (<a href="./references#CD013575-bbs2-0087" title="VerrottiA , StrianoP , IapadreG , ZagaroliL , BonanniP , CoppolaG , et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure2018;63:17-25. [PMID: 30391662]">Verrotti 2018</a>). The proposed mechanisms of action to explain the treatment of lamotrigine for bipolar disorder include inhibiting voltage‐sensitive sodium channels, glutamate release and calcium channel blockade (<a href="./references#CD013575-bbs2-0040" title="AndreazzaAC , YoungLT . The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. International Journal of Neuropsychopharmacology2014;17(7):1039-52.">Andreazza 2014</a>). To reduce the risk of life‐threatening skin rashes, lamotrigine needs to be titrated slowly. Thus, lamotrigine is more effective as maintenance therapy than in the acute treatment of bipolar disorder (<a href="./references#CD013575-bbs2-0045" title="BoboWV . The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clinic Proceedings2017;92(10):1532-51. [PMID: 28888714]">Bobo 2017</a>; <a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a>). Although the effects of lamotrigine on pregnancy have been reported in a previous systematic review, there was no association with birth defects or related disorders (<a href="./references#CD013575-bbs2-0077" title="ParienteG , LeibsonT , ShulmanT , Adams-WebberT , BarzilayE , NulmanI . Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs2017;31(6):439-50. [PMID: 28434134]">Pariente 2017</a>). Lamotrigine has been shown to demonstrate more predictable pharmacokinetics than other antiepileptic drugs such as carbamazepine and valproic acid or valproate, which have a pronounced interindividual variability in their pharmacokinetics and a narrow therapeutic range (<a href="./references#CD013575-bbs2-0062" title="JohannessenSI , TomsonT . Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Clinical Pharmacokinetics2006;45(11):1061-75. [PMID: 17048972]">Johannessen 2006</a>). As with other antiepileptic drugs, there are demonstrable effects of metabolic enzymes but oral bioavailability is almost 100%, with negligible influence from diets (<a href="./references#CD013575-bbs2-0054" title="GarnettWR . Lamotrigine: pharmacokinetics. Journal of Child Neurology1997;12 Suppl 1:S10-5. [PMID: 9429124]">Garnett 1997</a>). Consequently, treatment of lamotrigine is associated with less burden in blood sampling/therapeutic monitoring inflicted on people with bipolar disorder. </p> </section> <section id="CD013575-sec-0013"> <h3 class="title" id="CD013575-sec-0013">Why it is important to do this review</h3> <p>Reviews exploring the effectiveness of lamotrigine are available (<a href="./references#CD013575-bbs2-0047" title="BowdenCL , SinghV . Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy2012;13(17):2565-71. [PMID: 23140205]">Bowden 2012b</a>; <a href="./references#CD013575-bbs2-0094" title="YathamLN , KennedySH , ParikhSV , SchafferA , BondDJ , FreyBN , et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders2018;20(2)::97-170.">Yatham 2018</a>). However, these existing reviews considered non‐maintenance therapies as part of their scope, and the numbers of included studies and study participants were small. Consequently, we planned to conduct this Cochrane Review to synthesize the latest available evidence in order to provide a comprehensive update on the effectiveness of lamotrigine for maintenance treatment of bipolar disorder. Although lithium is used as the first‐line drug for the treatment of bipolar disorder, results from randomized studies on the comparative efficacy of lamotrigine versus lithium are inconsistent and thus we hoped to review and synthesize evidence using rigorous and systematic methods. We examined the effectiveness of lamotrigine against placebo as well as combination therapy and existing medications. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013575-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013575-sec-0014"></div> <p>To determine efficacy and safety of lamotrigine for the maintenance treatment of manic, depressive, and mixed episodes of bipolar disorder. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013575-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013575-sec-0015"></div> <section id="CD013575-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013575-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included individually‐randomized controlled trials. Cluster‐randomized trials were eligible for inclusion but none were identified. If studies employing a cross‐over design had been identified and included, we would only have used only data from the first active treatment (i.e. first randomized phase before crossing over). Studies published as full texts or only as abstracts as well as unpublished data were eligible for inclusion. </p> </section> <section id="CD013575-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with bipolar I or II disorder in remission, with a diagnosis based on the International Classification of Diseases 11th Revision (ICD‐11) coding system (<a href="./references#CD013575-bbs2-0093" title="World Health Organization. ICD-11. International Classification of Diseases 11th Revision. icd.who.int/en (accessed 6 July 2021).">WHO 2019b</a>), or the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM‐5) tool (or previous versions of these diagnostic manuals) (<a href="./references#CD013575-bbs2-0039" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association. 2013. Available from dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596.">American Psychiatric Association 2013</a>). Study participants were aged 18 years or older of either gender with concurrent primary diagnosis of Axis I or Axis II disorder. We included participants with any co‐morbidities except for those with dementia and personality disorder or cyclothymia, which was defined as a disorder not meeting the requirements to be classified as a major episode of hypomanic and depressive state. </p> </section> <section id="CD013575-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing lamotrigine with usual care, placebo or no treatment; the daily dosage of lamotrigine maintenance treatment was defined to range from 100 mg to 500 mg with a treatment duration of more than 12 weeks. </p> <p>We were interested in the following treatment comparisons:</p> <p> <ul id="CD013575-list-0001"> <li> <p>lamotrigine versus no treatment;</p> </li> <li> <p>lamotrigine versus placebo;</p> </li> <li> <p>lamotrigine versus lithium;</p> </li> <li> <p>lamotrigine versus valproic acid or valproate (or both);</p> </li> <li> <p>lamotrigine versus olanzapine;</p> </li> <li> <p>lamotrigine versus quetiapine;</p> </li> <li> <p>lamotrigine plus lithium versus lithium;</p> </li> <li> <p>lamotrigine plus lithium versus lamotrigine;</p> </li> <li> <p>lamotrigine plus valproic acid or valproate (or both) versus valproic acid or valproate (or both); </p> </li> <li> <p>lamotrigine plus valproic acid or valproate (or both) versus lamotrigine;</p> </li> <li> <p>lamotrigine plus olanzapine versus olanzapine;</p> </li> <li> <p>lamotrigine plus olanzapine versus lamotrigine;</p> </li> <li> <p>lamotrigine plus quetiapine versus quetiapine;</p> </li> <li> <p>lamotrigine plus quetiapine versus lamotrigine.</p> </li> </ul> </p> </section> <section id="CD013575-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p><b>Timing of outcome assessment</b> </p> <p>We anticipated that authors of studies would report response rates at various time points during and post‐intervention. Therefore, we subdivided the timing of outcome assessment as follows: </p> <p> <ul id="CD013575-list-0002"> <li> <p>short‐term effects, within 12 weeks after treatment initiation;</p> </li> <li> <p>long‐term effects, at 6 to 12 months after treatment initiation.</p> </li> </ul> </p> <p><b>Hierarchy of outcome measures</b> </p> <p>If several measures were available for each outcome, we used results from the Hamilton Depression Rating Scale (HDRS). If HDRS results were not available, we used results from the Montgomery‐Asberg Depression Rating Scale (MADRS) for depressive episode as the primary outcome. However, if outcomes were measured by other rating scales, we included and extracted these results with explanations on the components of the scale used by the respective included studies. </p> <section id="CD013575-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Our primary outcome measures of interests were as follows.</p> <p> <ul id="CD013575-list-0003"> <li> <p>Recurrence of any episode at one year:</p> <ul id="CD013575-list-0004"> <li> <p>hospitalization for any mood episodes;</p> </li> <li> <p>Young Mania Rating Scale (YMRS) total score ≥15 for manic episode (<a href="./references#CD013575-bbs2-0096" title="YoungRC , BiggsJT , ZieglerVE , MeyerDA . A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry1978;133:429-35.">Young 1978</a>); </p> </li> <li> <p>Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥ 15 for depressive episode (<a href="./references#CD013575-bbs2-0071" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134(4):382-9. [PMID: 444788]">Montgomery 1979</a>); Hamilton Depression Rating Scale (HDRS) total score ≥ 14 for depressive episode (<a href="./references#CD013575-bbs2-0060" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56-62.">Hamilton 1960</a>); </p> </li> <li> <p>clinical worsening with the need for additional treatment (e.g. mood stabilizers, antidepressants, antipsychotics or benzodiazepines); </p> </li> <li> <p>active suicidal behavior.</p> </li> </ul> </li> <li> <p>Withdrawal from treatment due to any reason:</p> <ul id="CD013575-list-0005"> <li> <p>short term, up to 12 weeks after treatment initiation (range: 7 to 16 weeks);</p> </li> <li> <p>long term, at least six months after treatment initiation (range: 6 to 16 months).</p> </li> </ul> </li> <li> <p>Adverse effects:</p> <ul id="CD013575-list-0006"> <li> <p>short term, up to 12 weeks after treatment initiation (range: 7 to 16 weeks);</p> </li> <li> <p>long term, at 6 to 12 months after treatment initiation (range: 6 to 16 months).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD013575-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We included the following secondary outcome measures:</p> <p> <ul id="CD013575-list-0007"> <li> <p>recurrence of manic episode at one year (based on assessor's judgement without using an evaluation scale); </p> </li> <li> <p>recurrence of depressive episode at one year (based on assessor's judgement without using an evaluation scale) ; </p> </li> <li> <p>quality of life as measured by the mental component summary of the 36‐Item Short Form Health Survey (SF‐36) (<a href="./references#CD013575-bbs2-0090" title="WareJE , SnowKK , KosinskiM , GandekB . SF-36 Health Survey: Manual and Interpretation Guide. Boston (MA): The Health Institute, New England Medical Centre, 1993.">Ware 1993</a>); </p> </li> <li> <p>total severity score calculated from adding depression and manic symptom scores, such as the HDRS and the YMRS (<a href="./references#CD013575-bbs2-0060" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56-62.">Hamilton 1960</a>; <a href="./references#CD013575-bbs2-0096" title="YoungRC , BiggsJT , ZieglerVE , MeyerDA . A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry1978;133:429-35.">Young 1978</a>). </p> </li> </ul> </p> <p>For timing of outcome assessment, we anticipated that authors of studies would report response rates at various time points during and post‐intervention. Therefore, we subdivided the timing of outcome assessment as follows: </p> <p> <ul id="CD013575-list-0008"> <li> <p>short term effects, up to 12 weeks after treatment initiation (range: 7 to 16 weeks);</p> </li> <li> <p>long term effects, at least six months after treatment initiation (range: 6 to 16 months). </p> </li> </ul> </p> <p>If several measures were available for each outcome, we used results from the HDRS. If HDRS results were unavailable, we used results from MADRS. However, if outcomes were measured by other rating scales not listed above, we included and extracted the relevant results with explanations on the components of the scale used by the respective included studies. </p> </section> </section> </section> <section id="CD013575-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013575-sec-0024"> <h4 class="title">Electronic searches</h4> <p>An information specialist from the Cochrane Common Mental Disorders Group searched the following databases on 21 May 2021 using relevant keywords, subject headings (controlled vocabularies) and search syntax, appropriate to each resource (<a href="./appendices#CD013575-sec-0112">Appendix 1</a>): </p> <p> <ul id="CD013575-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), (Issue 5 of 12, 2021) on the Cochrane Library; </p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR) (Issue 5 of 12, 2021) on the Cochrane Library; </p> </li> <li> <p>Ovid MEDLINE (1946 to May 21, 2021);</p> </li> <li> <p>Ovid Embase (1974 to 2021 Week 21);</p> </li> <li> <p>Ovid PsycINFO (to May Week 3 2021).</p> </li> <li> <p>Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) (all years to June 2016) (<a href="./appendices#CD013575-sec-0113">Appendix 2</a>). </p> </li> </ul> </p> <p>We searched ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), to identify unpublished or ongoing studies. </p> <p>We did not impose any restrictions on date, language or publication status to the searches. </p> </section> <section id="CD013575-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We screened reference lists of relevant narrative reviews and included studies for further relevant information. For information on unpublished data or ongoing studies, we attempted to contact the study investigators or content experts in the field (or both) in an attempt to identify additional trial data. </p> </section> </section> <section id="CD013575-sec-0026"> <h3 class="title" id="CD013575-sec-0026">Data collection and analysis</h3> <section id="CD013575-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (YH and KK) independently screened titles and abstracts from the systematic literature search and excluded clearly irrelevant records. For any disagreements, we consulted other review authors (TF or SS, or both). We identified and excluded duplicates and collated multiple reports of the same study so that each study, not each reference, was the unit of interest in the review. </p> <p>We retrieved full‐text versions of all 'to include' or 'unclear' records for further assessment against our pre‐defined eligibility criteria. We attempted to obtain translations of articles that were published in languages other than English or Japanese. For conference abstracts, we attempted to retrieve relevant subsequent full‐text publication or contacted the study investigators for clarification. Two review authors (YH and KK) independently screened the full texts against the pre‐specified inclusion/exclusion criteria. We resolved disagreements by discussion or by consulting other review authors (TF or SS, or both) </p> </section> <section id="CD013575-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (YH and KK) independently extracted the following information from included studies using a pre‐standardized data collection form. </p> <p> <ul id="CD013575-list-0010"> <li> <p>Methods: study design, total duration of study, methods of randomization, methods of allocation concealment, withdrawals. </p> </li> <li> <p>Participants: number, mean age, age range, gender, inclusion and exclusion criteria, diagnosis (bipolar disorder I type or type II), baseline comparability between two groups, severity of condition, mean scores on HDRS, or MADRS, or any other episode scale at baseline and end of studies, time from onset and losses to follow‐up. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcome data and characteristics.</p> </li> <li> <p>Others: setting, publication year, sources of funding, intention‐to‐treat (ITT) analysis.</p> </li> </ul> </p> <p>We resolved any disagreements regarding the extracted study information by discussion or by consulting other review authors (TF or SS, or both). </p> </section> <section id="CD013575-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (YH and KK) independently assessed risk of bias in included studies using Cochrane's tool for assessing risk of bias as indicated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We resolved disagreements by discussion or by consulting other review authors (TF or SS, or both). </p> <p>We assessed risk of bias in included studies according to the following seven domains:</p> <p> <ol id="CD013575-list-0011"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We judged each potential source of bias as 'high risk', 'low risk' or 'unclear risk', and provided a supporting quotation from the study report together with a justification for our judgements in the risk of bias table. We summarized our judgements across different studies for each domain. </p> </section> <section id="CD013575-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>If the included studies reported continuous data such as total severity scores using the same measurement scale, we planned to synthesize the effect measures using mean differences (MDs) with 95% confidence intervals (CIs); had studies used different measurement tools, we planned to calculate the standardized mean differences (SMDs). For dichotomous data such as the number of reported adverse effects, we calculated the risk ratios (RRs) with 95% CIs. </p> </section> <section id="CD013575-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <section id="CD013575-sec-0032"> <h5 class="title">Cross‐over studies</h5> <p>One concern of cross‐over trials is the carry‐over effect, where the anticipated and unprecedented pharmacological, physiological and psychological effects of the study treatment intervention in the first phase may affect the results of the second phase of the study. As a result, in the second phase, participants can differ systematically from their initial state, even after a washout period. </p> <p>For the purpose of this Cochrane Review, had we included cross‐over studies, we would have considered only results from the first phase, i.e. prior to crossing over. </p> </section> <section id="CD013575-sec-0033"> <h5 class="title">Cluster‐randomized trials</h5> <p>For cluster‐randomized trials, we planned to make an adjustment to the sample size for each intervention based on the method described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>), using an estimate of the intraclass correlation coefficient (ICC) derived from the study (where available) or from a similar study or from a study of a similar population. We intended to conduct a sensitivity analysis to explore the effects of variation in ICCs and the overall robustness of our findings (<a href="#CD013575-sec-0040">Sensitivity analysis</a>). Impact of studies for which no ICC was reported on the overall review findings would have been explored in a sensitivity analysis (<a href="#CD013575-sec-0040">Sensitivity analysis</a>). </p> </section> <section id="CD013575-sec-0034"> <h5 class="title">Studies with multiple treatment groups</h5> <p>Where a relevant study involved more than two treatments groups, we included data from the additional arms for comparisons. If the data were binary, we combined them in a 2 × 2 table. If data were continuous, we combined them using the formula provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> <p> </p> </section> </section> <section id="CD013575-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We recorded missing data for each included study and attempted to contact the study investigators for the missing information. Where possible, we performed all meta‐analyses using an intention‐to‐treat (ITT) approach i.e. we analyzed all participants and their outcomes within the groups to which they were originally allocated, regardless of whether they received the intervention. </p> </section> <section id="CD013575-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by visually inspecting the calculated effect estimates and CIs in the forest plots. We used the Chi<sup>2</sup> test (statistical significance at P &lt; 0.1) and the I<sup>2</sup> statistic to investigate and quantify statistical heterogeneity in each meta‐analysis. We interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>): </p> <p> <ul id="CD013575-list-0012"> <li> <p>0% to 40% might not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100% represents considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD013575-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when dissemination of research findings is often influenced by the nature and direction of the results (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We planned to conduct a funnel plot to investigate publication bias through visual inspection of asymmetry should sufficient evidence be available (10 or more included studies) for each outcome, also planned to perform a statistical test for funnel plot asymmetry as proposed by Egger and Rücker (<a href="./references#CD013575-bbs2-0053" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9310563]">Egger 1997</a>; <a href="./references#CD013575-bbs2-0080" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine2008;27(5):746-63. [PMID: 17592831]">Rücker 2008</a>). </p> </section> <section id="CD013575-sec-0038"> <h4 class="title">Data synthesis</h4> <p>One review author (KK) entered data into the RevMan web, and a second review author (YH) checked the entries. Due to variations in participants, interventions or outcomes, we used a random‐effects meta‐analysis to produce an overall summary.  </p> </section> <section id="CD013575-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following four subgroup analyses for our <a href="#CD013575-sec-0021">Primary outcomes</a> should data be sufficient: </p> <p> <ul id="CD013575-list-0013"> <li> <p>with or without mental disorder co‐morbidities;</p> </li> <li> <p>duration of treatment (up to six months and longer than six months);</p> </li> <li> <p>setting (community versus hospital);</p> </li> <li> <p>for each pharmacological modality such as mood stabilizer, antipsychotic and antidepressant.</p> </li> </ul> </p> </section> <section id="CD013575-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct a sensitivity analysis to examine the impact of the ICCs (<a href="#CD013575-sec-0031">Unit of analysis issues</a>) mentioned above.  </p> <p>In addition, sensitivity analyses were also planned under the following conditions to determine if the risk area of bias would affect the overall robustness of the findings: </p> <p> <ul id="CD013575-list-0014"> <li> <p>excluding studies with inadequate allocation concealment and random sequence generation;</p> </li> <li> <p>excluding studies in which outcome evaluation was not blinded;</p> </li> <li> <p>excluding studies in which loss to follow‐up was not reported or was greater than 10%; </p> </li> <li> <p>excluding studies funded by the pharmaceutical company marketing lamotrigine.</p> </li> </ul> </p> </section> <section id="CD013575-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings table based on the GRADE assessment system using the <a href="./references#CD013575-bbs2-0056" title="GRADEpro GDT. Version accessed 6 July 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 6 July 2021. Available at gradepro.org.">GRADEpro GDT</a> software for each of the main comparisons, considering the two most clinically important primary outcomes (<a href="./references#CD013575-bbs2-0059" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [PMID: 21195583]">Guyatt 2011</a>). Two review authors (YH and KK) independently graded the body of evidence using adapted decision rules. We explored the following five domains: </p> <p> <ol id="CD013575-list-0015"> <li> <p>risk of bias;</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness;</p> </li> <li> <p>imprecision;</p> </li> <li> <p>and publication bias.</p> </li> </ol> </p> <p>We graded the overall strength of evidence for each outcome as 'high', 'moderate', 'low' or 'very low', and resolved any disagreement through discussion or by consulting a third author (TF or NW). </p> <p>We included the following outcomes in the summary of findings tables.</p> <p> <ul id="CD013575-list-0016"> <li> <p>Recurrence of any episode at one year:</p> <ul id="CD013575-list-0017"> <li> <p>hospitalization for any mood episodes;</p> </li> <li> <p>YMRS total score ≥15 for manic episode;</p> </li> <li> <p>MADRS total score ≥15 for depressive episode; and HDRS total score ≥14 for depressive episode; </p> </li> <li> <p>clinical worsening with the need for addition of a mood stabilizer, antidepressant treatment, antipsychotic medication or benzodiazepine; or </p> </li> <li> <p>active suicidal behavior.</p> </li> </ul> </li> <li> <p>Withdrawal from treatment due to any reason:</p> <ul id="CD013575-list-0018"> <li> <p>short term, up to 12 weeks after treatment initiation (range: 7 to 16 weeks);</p> </li> <li> <p>long term, at least six months after treatment initiation (range: 6 to 16 months).</p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013575-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013575-sec-0042"></div> <section id="CD013575-sec-0043"> <h3 class="title">Description of studies</h3> <p>Lamotrigine in the maintenance treatment of bipolar disorder</p> <section id="CD013575-sec-0044"> <h4 class="title">Results of the search</h4> <p>Searches of the Cochrane Library (CENTRAL and CDSR), MEDLINE, Embase, PsycINFO, and CCMDCTR databases yielded a total of 1708 records (updated to include searches up to May 2021). <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> written in Japanese was not retrieved by searching these electrical database, but from screening of the reference list of <a href="./references#CD013575-bbs2-0076" title="OyaK , SakumaK , EsumiS , HashimotoY , HatanoM , MatsudaY , et al. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology Reports2019;39(3):241-6. [PMID: 31026388]">Oya 2019</a>. Of those initial 1709 studies, we identified 142 studies as potentially eligible for inclusion after title and abstract screening. We retrieved full‐text articles for these 142 studies for full inspection, of which 134 were excluded and finally, 11 studies (eight papers) fulfilled our inclusion criteria and were included in the review. Our study selection process is illustrated in <a href="#CD013575-fig-0001">Figure 1</a> (<a href="./references#CD013575-bbs2-0070" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine2009;151(4):264-9. [PMID: 19622511]">Moher 2009</a>). </p> <div class="figure" id="CD013575-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD013575-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> </section> <section id="CD013575-sec-0045"> <h4 class="title">Included studies</h4> <p>Please refer to <a href="./references#CD013575-sec-0122" title="">Characteristics of included studies</a> for further information. </p> <p>We included 11 studies in this review (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). We identified one publication which reported findings from five RCTs; of these, one (GW602/SCAB2001) was the duplication of <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>. Therefore, this was excluded and the remaining four studies were included in this review (<a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). Please note we have listed these trial names as per the original publication. </p> <section id="CD013575-sec-0046"> <h5 class="title">Study design and settings</h5> <p>All included studies were multicenter randomized trials; all but one study applied double‐blind methodology (<a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). We did not identify any cluster‐randomized studies. </p> </section> <section id="CD013575-sec-0047"> <h5 class="title">Study duration</h5> <p>The length of study ranged from seven to 302 weeks: <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, seven weeks;  <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>, eight weeks; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>, 10 weeks. Treatment duration ranged from 16 weeks to 5.8 years: <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>, 16 weeks; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>, 26 weeks; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, six months; <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a> and <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>, 76 weeks; and in <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a> treatment continued for 5.8 years. Our analysis was stratified according to the study period (short term and long term). We defined study duration of seven to 16 weeks as "short term" and duration of over six months as "long term". </p> </section> <section id="CD013575-sec-0048"> <h5 class="title">Sample sizes</h5> <p>The 11 included studies involved a total 2314 participants: 1146 were randomized to lamotrigine, 869 were randomized to placebo and 299 to lithium. </p> <p><a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>, <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>, and <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> were the only studies that reported sample size calculations. </p> </section> <section id="CD013575-sec-0049"> <h5 class="title">Participants</h5> <p>Of the 11 included studies, participants were diagnosed with bipolar I disorder in seven studies (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). Participants from <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, and <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a> were diagnosed with bipolar I as well as bipolar II disorders. Two studies included patients with bipolar II disorder (<a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). </p> <p>In the open‐label phase, 38.5% of participants were treated with lamotrigine prior to double‐blinded randomization phase (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>); in <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>, the proportion of pre‐randomization use of lamotrigine was 53.9%. No description of medications used prior to randomization was available in <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>, <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>, <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>. Only <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was a single‐blind randomized study. Therefore, it was an open‐label study throughout the study duration (4.1%). </p> <p>Participants included in each of the 11 included studies were hospital outpatients of both genders; in six studies, participants were aged at least 18 years old (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). The inclusion criterion for <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> was limited to adults aged 20 years or above (<a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>). In the remaining four studies, no description of specific age range/cut‐offs were provided besides describing their participants as “adults” (<a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). </p> <p>All the study participants were diagnosed with bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (DSM‐IV, DSM‐IV‐TR), assessed by a variety of instruments including the Structured Clinical Interview for DSM Disorders (SCID) as illustrated in <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> and <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>. </p> </section> <section id="CD013575-sec-0050"> <h5 class="title">Interventions and comparators</h5> <p>Types of comparisons were as follows: seven studies comparing lamotrigine with placebo (<a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>), two investigated lamotrigine versus lithium (<a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>), and two were three‐arm studies comparing lamotrigine with lithium as well as placebo (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>). </p> <p>During the open‐label phase, the dosing schedule of lamotrigine used in <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was as follows: weeks 1 to 2, 25 mg/day; weeks 3 to 4, 50 mg/day; week 5, 75 mg/day; week 6, 100 mg/day; week 7, 150 mg/day; and week 8, 200 mg/day. In the other included studies, lamotrigine dose was escalated to reach a target dose as follows: weeks to ‐2, 25 mg/day; weeks 3 to 4, 50 mg/day; week 5, 10 0mg/day; and week 6, 200 mg/day. After six weeks, the daily dose was adjusted depending on tolerability, with a flexible dosing regimen from 100 mg to 500 mg daily in the maintenance phase. </p> </section> <section id="CD013575-sec-0051"> <h5 class="title">Outcomes</h5> <p>The 11 included studies reported the following outcome measures.</p> <p> <ol id="CD013575-list-0019"> <li> <p>Recurrence of manic episodes at one year measured by the Young Mania Rating Scale (YMRS) (<a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>) and  Mania Rating Scale (MRS) (<a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>). </p> </li> <li> <p>Recurrent of depressive episodes at one year by the Hamilton Depression Rating Scale (HDRS) (<a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). </p> </li> <li> <p>Addition of any psychotropics for recurrence of any episodes at one year (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). </p> </li> <li> <p>Active suicidal behavior (<a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). </p> </li> <li> <p>Withdrawal from treatment by any reason up to 12 weeks after the intervention i.e. short‐term withdrawal (<a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>). </p> </li> <li> <p>Withdrawal from treatment due to any reason at six‐ to12 months after the intervention i.e. long‐term withdrawal (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). </p> </li> <li> <p>Any reported adverse effects (number of participants who experienced at least one adverse effect) up to 12 weeks after the intervention i.e. short‐term safety (<a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). </p> </li> <li> <p>Any reported adverse effects (number of participants who experienced at least one adverse effect) six to 12 months after the intervention i.e. long‐term safety (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). </p> </li> <li> <p>Recurrence of manic episode (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). </p> </li> <li> <p>Recurrence of depressive episode (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). </p> </li> </ol> </p> <p>None of the included studies reported data on quality of life or satisfaction with treatment outcomes.  </p> </section> </section> <section id="CD013575-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies from this review (see <a href="#CD013575-fig-0001">Figure 1</a>). The most common reason of exclusion was inappropriate study inclusion criteria. Other reasons were wrong type(s) of intervention(s), wrong outcome measures, wrong study designs (e.g. non‐randomized controlled trials (RCTs)), and the lack of relevant data (<a href="./references#CD013575-sec-0123" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD013575-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>Findings of our assessment of risk of bias in included studies are illustrated in <a href="#CD013575-fig-0002">Figure 2</a> and <a href="#CD013575-fig-0003">Figure 3</a> for the specific judgments. Further details and justification of our judgments are presented in the <a href="./references#CD013575-sec-0122" title="">Characteristics of included studies</a> section.  </p> <div class="figure" id="CD013575-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt=". Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013575-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="#CD013575-fig-0002">Figure 2</a>. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013575-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt=". Risk of bias table" data-id="CD013575-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="#CD013575-fig-0003">Figure 3</a>. Risk of bias table </p> </div> </div> </div> <section id="CD013575-sec-0054"> <h4 class="title">Allocation</h4> <p>Nine studies did not report details on the sequence generation and were judged as having an unclear risk of bias (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). Two studies provided sufficient information on sequence generation (<a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). </p> <p>Eight studies failed to provide details on how allocation was concealed and were thus judged as having an unclear risk of bias (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>). Two studies provided sufficient information on allocation concealment and we judged them as having low risk of bias (<a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was described as an open‐label study and thus we classified it as high risk of bias. </p> </section> <section id="CD013575-sec-0055"> <h4 class="title">Blinding</h4> <section id="CD013575-sec-0056"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We classified nine studies included in the review as being at low risk of performance bias, as participants and personal were explicitly described as blinded in the study report (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>). We classified one trial as being unclear because it provided no information on blinding participants or personnel (<a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was described as an open‐label study and thus we classified it as high risk of bias. </p> </section> <section id="CD013575-sec-0057"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>We rated one trial as having a low risk of detection bias (<a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>); five trials as having a high risk of detection bias (<a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a> <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>). The remaining trials did not provide details on the blinding of outcome assessors and thus were judged to be of unclear risk of bias (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). </p> </section> </section> <section id="CD013575-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We rated six trials to be adequate in terms of addressing incomplete outcome data (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). One trial had unclear risk of attrition bias (<a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>), and the remaining four trials were assessed to be at high risk of bias since they lacked clear description of study methodology (<a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). </p> </section> <section id="CD013575-sec-0059"> <h4 class="title">Selective reporting</h4> <p>On the whole, study authors diligently reported study data and thus we assessed all included studies to be at low risk of reporting bias (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a>; <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>). </p> </section> <section id="CD013575-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify other potential sources of bias amongst the 11 included studies.</p> </section> </section> <section id="CD013575-sec-0061"> <h3 class="title" id="CD013575-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD013575-tbl-0001"><b>Summary of findings 1</b> Lamotrigine versus placebo for the maintenance treatment of bipolar disorder</a>; <a href="./full#CD013575-tbl-0002"><b>Summary of findings 2</b> Lamotrigine versus lithium for the maintenance treatment of bipolar disorder</a> </p> <section id="CD013575-sec-0062"> <h4 class="title">Comparison 1: Lamotrigine versus no treatment</h4> <p>See <a href="./full#CD013575-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013575-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD013575-sec-0064"> <h6 class="title">Hospitalization for any mood episode</h6> <p>No trial measured this outcome.</p> </section> <section id="CD013575-sec-0065"> <h6 class="title">Young Mania Rating Scale (YMRS) total score ≥ 15 for manic episode</h6> <p>Three trials provided data on the YMRS total score ≥ 15 for manic episode, enrolling a total of 663 participants. But only one study contributed to the meta‐analysis because the other two studies had zero events. We found a difference between lamotrigine and placebo (RR 0.67, 95% CI 0.51 to 0.87; P = 0.003) in favor of lamotrigine; low‐certainty evidence (<a href="./references#CD013575-fig-0004" title="">Analysis 1.1</a>).  </p> </section> <section id="CD013575-sec-0066"> <h6 class="title">Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥ 15 depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥ 14 for depressive episode </h6> <p>Seven trials provided data on the MADRS total score ≥ 15 for depressive episodes or HDRS total score ≥ 14 for depressive episodes, including a total of 1606 participants. There was no difference between lamotrigine and placebo (RR 0.85, 95% CI 0.70 to 1.02; P = 0.08; low‐certainty evidence <a href="./references#CD013575-fig-0005" title="">Analysis 1.2</a>), with substantial heterogeneity (I<sup>2</sup> = 71%; P = 0.002). </p> </section> <section id="CD013575-sec-0067"> <h6 class="title">Clinical worsening with the need for additional treatment (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </h6> <p>Four trials (n=756) provided data on clinical worsening with the need of additional treatment. We found a difference between lamotrigine and placebo (RR 0.82, 95% CI 0.70 to 0.98; P = 0.03) in favor of lamotrigine; moderate‐certainty evidence (<a href="./references#CD013575-fig-0006" title="">Analysis 1.3</a>). Heterogeneity was found to be not important (I<sup>2</sup> = 31%; P = 0.23). </p> </section> <section id="CD013575-sec-0068"> <h6 class="title">Active suicidal behavior</h6> <p>None of the included trials measured this a priori outcome.</p> </section> <section id="CD013575-sec-0069"> <h6 class="title">Withdrawal from treatment due to any reason (short term)</h6> <p>Only one trial of 195 participants provided data on treatment withdrawal due to any reason (short term), and we found no difference between lamotrigine and placebo (RR 1.10, 95% CI 0.70 to 1.74; P = 0.67; very low‐certainty evidence <a href="./references#CD013575-fig-0007" title="">Analysis 1.4</a>).  </p> </section> <section id="CD013575-sec-0070"> <h6 class="title">Withdrawal from treatment due to any reason (long term)</h6> <p>Four trials of 700 participants assessed treatment withdrawal due to any reason (long term). Treatment of lamotrigine was associated with a reduced incidence of treatment withdrawal as compared to placebo (RR 0.88, 95% CI 0.78 to 0.99; P = 0.03; moderate‐certainty evidence <a href="./references#CD013575-fig-0008" title="">Analysis 1.5</a>), with moderate heterogeneity (I<sup>2</sup> = 37%; P = 0.19). </p> </section> <section id="CD013575-sec-0071"> <h6 class="title">Adverse effects (short term)</h6> <p>Five trials reported adverse effects (short term), enrolling a total of 1138 participants. There was no difference between lamotrigine and placebo (RR 1.07, 95% CI 0.81 to 1.42; P = 0.61; very low‐certainty evidence <a href="./references#CD013575-fig-0009" title="">Analysis 1.6</a>); heterogeneity was moderate (I<sup>2</sup> = 42%; P = 0.14). </p> </section> <section id="CD013575-sec-0072"> <h6 class="title">Adverse effects (long term)</h6> <p>Four trials provided data on adverse effects (long term), including a total of 756 participants. We found no difference between the two groups (RR 0.97, 95% CI 0.77 to 1.23; P = 0.83; moderate‐certainty evidence <a href="./references#CD013575-fig-0010" title="">Analysis 1.7</a>), with moderate heterogeneity (I<sup>2</sup> = 45%; P = 0.14). </p> </section> </section> <section id="CD013575-sec-0073"> <h5 class="title">Secondary outcomes</h5> <section id="CD013575-sec-0074"> <h6 class="title">Recurrence of manic episode at one year</h6> <p>Three trials of 574 participants assessed recurrence of manic episode. We found no difference between lamotrigine and placebo (RR 0.91, 95% CI 0.66 to 1.26; P = 0.58; moderate‐certainty evidence <a href="./references#CD013575-fig-0011" title="">Analysis 1.8</a>). We found no heterogeneity (I<sup>2</sup> = 0%; P = 0.59). </p> </section> <section id="CD013575-sec-0075"> <h6 class="title">Recurrence of depressive episode at one year</h6> <p>Three trials provided data on the recurrence of depressive episode, enrolling a total of 574 participants. We found a difference between lamotrigine and placebo (RR 0.75, 95% CI 0.53 to 1.05; P = 0.09) in favor of lamotrigine moderate‐certainty evidence (<a href="./references#CD013575-fig-0012" title="">Analysis 1.9</a>). Heterogeneity was moderate for this outcome (I<sup>2</sup> = 37%; P = 0.21). </p> </section> <section id="CD013575-sec-0076"> <h6 class="title">Quality of life</h6> <p>No trial measured this outcome.</p> </section> <section id="CD013575-sec-0077"> <h6 class="title">Total severity score</h6> <p>No trial measured this outcome.</p> </section> </section> </section> <section id="CD013575-sec-0078"> <h4 class="title">Comparison 2: Lamotrigine versus lithium</h4> <p>See <a href="./full#CD013575-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013575-sec-0079"> <h5 class="title">Primary outcomes</h5> <section id="CD013575-sec-0080"> <h6 class="title">Hospitalization for any mood episode</h6> <p>No trial measured this outcome.</p> </section> <section id="CD013575-sec-0081"> <h6 class="title">Young Mania Rating Scale (YMRS) total score ≥ 15 for manic episode</h6> <p>Two trials of 376 participants provided data on the YMRS total score 15 or greater for manic episode and there was no difference between the two groups. (RR 3.57, 95% CI 0.15 to 85.39; P = 0.43; very low‐certainty evidence <a href="./references#CD013575-fig-0013" title="">Analysis 2.1</a>). Heterogeneity was not applicable. </p> </section> <section id="CD013575-sec-0082"> <h6 class="title">Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥ 15 depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥ 14 for depressive episode </h6> <p>Two trials reported the MADRS total score ≥ 15 for depressive episode or HDRS total score ≥14 for depressive episode, including a total of 376 participants. We found no difference between lamotrigine and placebo (RR 1.40, 95% CI 0.70 to 2.79; P = 0.34; low‐certainty evidence <a href="./references#CD013575-fig-0014" title="">Analysis 2.2</a>). Heterogeneity was not applicable. </p> </section> <section id="CD013575-sec-0083"> <h6 class="title">Clinical worsening with the need for additional treatment (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </h6> <p>Three trials of 602 participants assessed clinical worsening with the use of additional treatment. There was no difference between lamotrigine and lithium (RR 1.11, 95% CI 0.92 to 1.35; P = 0.28; moderate‐certainty evidence <a href="./references#CD013575-fig-0015" title="">Analysis 2.3</a>). We found no important heterogeneity (I<sup>2</sup> = 0%; P = 0.73). </p> </section> <section id="CD013575-sec-0084"> <h6 class="title">Active suicidal behavior</h6> <p>We identified just one trial (n = 155) with data on active suicidal behavior. There was no difference between lamotrigine and placebo (RR 1.01, 95% CI 0.06 to 15.91; P = 0.99; very low‐certainty evidence <a href="./references#CD013575-fig-0016" title="">Analysis 2.4</a>). </p> </section> <section id="CD013575-sec-0085"> <h6 class="title">Withdrawal from treatment due to any reason (short term)</h6> <p>None the included trials measured this pre‐specified outcome.</p> </section> <section id="CD013575-sec-0086"> <h6 class="title">Withdrawal from treatment due to any reason (long term)</h6> <p>Four trials provided data on treatment withdrawal due to any reason (long term), including a total of 636 participants. No difference between groups was observed (RR 0.96, 95% CI 0.88 to 1.05; P = 0.34; moderate‐certainty evidence <a href="./references#CD013575-fig-0017" title="">Analysis 2.5</a>); heterogeneity was found to be minimal (I<sup>2</sup> = 4%; P = 0.37). </p> </section> <section id="CD013575-sec-0087"> <h6 class="title">Adverse effects (short term)</h6> <p>None of the included trial measured this outcome.</p> </section> <section id="CD013575-sec-0088"> <h6 class="title">Adverse effects (long term)</h6> <p>Four trials assessed long‐term adverse effect amongst 691 participants. We found a difference between lamotrigine and lithium (RR 0.70, 95% CI 0.51 to 0.96; P = 0.02) in favor of lamotrigine moderate‐certainty evidence (<a href="./references#CD013575-fig-0018" title="">Analysis 2.6</a>). Heterogeneity was found to be moderate (I<sup>2</sup> = 37%; P = 0.19). </p> </section> </section> <section id="CD013575-sec-0089"> <h5 class="title">Secondary outcomes</h5> <section id="CD013575-sec-0090"> <h6 class="title">Recurrence of manic episode at one year</h6> <p>Three trials provided data on the recurrence of manic episode, including a total of 602 participants. We noted a higher incidence of recurrent manic episode with lamotrigine versus lithium (RR 2.13, 95% CI 1.32 to 3.44; P = 0.002; moderate‐certainty evidence <a href="./references#CD013575-fig-0019" title="">Analysis 2.7</a>), with no heterogeneity (I<sup>2</sup> = 0%; P = 0.43). </p> </section> <section id="CD013575-sec-0091"> <h6 class="title">Recurrence of depressive episode at one year</h6> <p>Three trials (602 participants) assessed the recurrence of depressive episode. There was no difference between the two groups (RR 0.83, 95% CI 0.63 to 1.09; P = 0.18; moderate‐certainty evidence <a href="./references#CD013575-fig-0020" title="">Analysis 2.8</a>). We found no important heterogeneity (I<sup>2</sup> = 2%; P = 0.36). </p> </section> <section id="CD013575-sec-0092"> <h6 class="title">Quality of life</h6> <p>None of the included trials measured this outcome.</p> </section> <section id="CD013575-sec-0093"> <h6 class="title">Total severity score</h6> <p>None of the included trials measured this a priori outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013575-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013575-sec-0094"></div> <section id="CD013575-sec-0095"> <h3 class="title" id="CD013575-sec-0095">Summary of main results</h3> <p>Our review included 11 studies involving 2314 participants. We found low‐certainty evidence supporting the use of lamotrigine over placebo for people with bipolar disorder. Lamotrigine was found to be more effective than placebo for minimizing recurrence of bipolar depression at one year. Moderate‐certainty evidence indicated that lamotrigine a similar safety profile compared to placebo. Treatment withdrawal at 6 to 12 months was more frequent amongst participants in the placebo groups when compared with the lamotrigine groups.  </p> <p>Compared to lithium, we found low‐certainty evidence indicating that lamotrigine was comparable to lithium in the outcomes of bipolar disorder symptoms except for recurrence of bipolar mania. Current evidence also found that lamotrigine increased incidence of exacerbated bipolar manic symptoms when compared to lithium. In addition, adverse events experienced by participants treated with lamotrigine were lower than those reported in the lithium groups. </p> </section> <section id="CD013575-sec-0096"> <h3 class="title" id="CD013575-sec-0096">Overall completeness and applicability of evidence</h3> <p>We conducted a comprehensive and systematic literature search to identify all available published and unpublished studies fulfilling our pre‐specified inclusion criteria, and 11 studies were eventually included. Of these, seven studies compared lamotrigine with placebo, two were three‐arm studies that investigated the effects of lamotrigine versus lithium versus placebo, and the remaining two studies compared lamotrigine with lithium. </p> <p>Overall, all the included studies reported our efficacy outcomes of interest. We performed data conversion (from continuous to dichotomous data) using indicated average, standard deviation, and sample numbers (<a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>; <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>; <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>; <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a>; <a href="./references#CD013575-bbs2-0005" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [GW603/SCAA2010]</a>; <a href="./references#CD013575-bbs2-0006" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00274677. Depression and bipolar disorder [A multicenter, double-blind, placebo-controlled, fixed-dose, 8-week evaluation of the efficacy and safety of lamotrigine in the treatment of depression in patients with type II bipolar disorder]. clinicaltrials.gov/ct2/show/NCT00274677 (first received 11 January 2006). ">Calabrese 2008 [SCA100223]</a>; <a href="./references#CD013575-bbs2-0007" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. NCT00056277. Bipolar disorder study for men and women [Double blind placebo controlled study of lamictal in acute bipolar depression]. clinicaltrials.gov/ct2/show/NCT00056277 (first received 11 March 2003). ">Calabrese 2008 [SCA30924]</a>; <a href="./references#CD013575-bbs2-0008" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 2008 [SCA40910]</a>; <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a>). As a result, we were able to synthesize evidence for the various efficacy outcomes in the comparisons of lamotrigine versus placebo and lamotrigine versus lithium. None of the included studies assessed hospitalization for any mood episode, quality of life, or total change score Young Mania Rating Scale (YMRS) plus: Hamilton Depression Rating Scale (HDRS)). Reporting of adverse events was generally adequate, which allowed for evaluation of safety outcomes. </p> <p>All our studies enrolled adults with clinically‐diagnosed bipolar disorder (as confirmed by: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM‐IV)) and were conducted in the outpatient setting from several countries. </p> <p>In this review we attempted to ensure the highest possible level of certainty of the evidence, we excluded non‐randomized studies or randomized controlled trials (RCTs) that did not use a standard diagnostic process. Our review findings showed that lamotrigine was more effective than placebo on recurrence of bipolar disorder, and the incidence of adverse events was comparable between groups. Furthermore, lamotrigine was found to be more tolerable than lithium, which has been the standard treatment approach in clinical practice. The key to treatment during the maintenance phase of bipolar disorder is continuity of treatment. Considering these facts, we would like to highlight that lamotrigine poses as a viable treatment option. </p> </section> <section id="CD013575-sec-0097"> <h3 class="title" id="CD013575-sec-0097">Quality of the evidence</h3> <p>We assessed the certainty of the evidence collected using the GRADE approach, which takes into consideration five domains: risk of bias, inconsistency, indirectness, imprecision and publication bias. Elaboration of our GRADE assessment for each outcome is illustrated in <a href="./full#CD013575-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013575-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013575-sec-0098"> <h4 class="title">Overall GRADE assessment</h4> <p> <ul id="CD013575-list-0020"> <li> <p>Lamotrigine versus placebo: evidence on efficacy outcomes was generally of low to moderate certainty. Overall, the number of included studies was small and thus we could not assess publication bias. Included evidence regarding adverse effects of lamotrigine was judged to be of very low certainty in the short‐term duration and of moderate certainty in the long term. </p> </li> <li> <p>Lamotrigine versus lithium: certainty of evidence on efficacy outcomes was moderate. Only limited study findings were available and we decided to not investigate publication bias. Certainty of evidence on the comparative adverse effect profiles of lamotrigine was assessed to be moderate. </p> </li> </ul> </p> </section> <section id="CD013575-sec-0099"> <h4 class="title">Risk of bias</h4> <p>We rated all included studies as having an unclear risk of bias in at least one domain of the Cochrane Collaboration’s tool for assessing risk of bias (<a href="./references#CD013575-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews ofInterventions version 6.1 (updated September 2020). Cochrane,2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>), with the most commonly observed weakness being selection bias (random sequence generation and allocation concealment). We judged seven of the nine included studies as having a high risk of bias in at least one domain; among these, six studies showed a high risk of detection bias (blinding of outcome assessment). These potential biases pose a major threat to the validity of the review findings. </p> </section> <section id="CD013575-sec-0100"> <h4 class="title">Inconsistency</h4> <p>Substantial statistical heterogeneity across studies was noted in the outcome of recurrence of any episodes at one year (MADRS total score ≥15 for depressive episode or HDRS total score ≥14 for depressive episode) for the comparison of lamotrigine versus placebo, which limited the reliability of the included evidence and we downgraded the level of certainty accordingly. </p> </section> <section id="CD013575-sec-0101"> <h4 class="title">Indirectness</h4> <p>Overall, the available evidence matched well with our pre‐defined clinical questions and review scope. The included study subjects were all hospital outpatients during the maintenance phase of bipolar I or II disorder. </p> </section> <section id="CD013575-sec-0102"> <h4 class="title">Imprecision</h4> <p>The precision of our outcome estimates was significantly hampered by several factors, such as very wide confidence intervals and small size of some of studies. </p> </section> <section id="CD013575-sec-0103"> <h4 class="title">Publication bias</h4> <p>We did not assess publication bias using a funnel plot as none of the analyses included more than 10 studies. </p> </section> </section> <section id="CD013575-sec-0104"> <h3 class="title" id="CD013575-sec-0104">Potential biases in the review process</h3> <p>We conducted an extensive search for randomized studies meeting our pre‐defined eligibility criteria. Nevertheless, we found insufficient data available to fully answer our review questions and numerous outcomes had only a small number of included studies. As a result, we were unable to conduct subgroup analyses and sensitivity analyses as planned at the protocol stage; however, we did not find any sources of bias that might be expected to affect the study results. On the other hand, of the 11 studies we included, eight were funded by the same sponsor and thus we cannot rule out the potential of industry sponsorship bias, which could lead to an overestimation of interventions.  </p> </section> <section id="CD013575-sec-0105"> <h3 class="title" id="CD013575-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>Our results are consistent with the results of four previous systematic reviews (<a href="./references#CD013575-bbs2-0043" title="BeynonS , Soares-WeiserK , WoolacottN , DuffyS , GeddesJR . Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Journal of Psychopharmacology2009;23(5):574-91.">Beynon 2009</a>; <a href="./references#CD013575-bbs2-0069" title="MiuraT , NomaH , FurukawaTA , MitsuyasuH , TanakaS , StocktonS , et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry2014;1(5):351-9. [PMID: 26360999]">Miura 2014</a>; <a href="./references#CD013575-bbs2-0076" title="OyaK , SakumaK , EsumiS , HashimotoY , HatanoM , MatsudaY , et al. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology Reports2019;39(3):241-6. [PMID: 31026388]">Oya 2019</a>; <a href="./references#CD013575-bbs2-0082" title="SmithLA , CorneliusV , WarnockA , BellA , YoungAH . Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders2007;9(4):394-412. [PMID: 17547586]">Smith 2007</a>). Lamotrigine was shown to be superior over placebo in reducing relapse of any mood episode. Although lamotrigine showed no benefits in bipolar manic episode, lamotrigine was more effective than placebo in reducing bipolar depressive episode (<a href="./references#CD013575-bbs2-0043" title="BeynonS , Soares-WeiserK , WoolacottN , DuffyS , GeddesJR . Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Journal of Psychopharmacology2009;23(5):574-91.">Beynon 2009</a>; <a href="./references#CD013575-bbs2-0082" title="SmithLA , CorneliusV , WarnockA , BellA , YoungAH . Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders2007;9(4):394-412. [PMID: 17547586]">Smith 2007</a>). As for adverse effects, lamotrigine was found to be better tolerated than lithium (<a href="./references#CD013575-bbs2-0069" title="MiuraT , NomaH , FurukawaTA , MitsuyasuH , TanakaS , StocktonS , et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry2014;1(5):351-9. [PMID: 26360999]">Miura 2014</a>; <a href="./references#CD013575-bbs2-0082" title="SmithLA , CorneliusV , WarnockA , BellA , YoungAH . Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders2007;9(4):394-412. [PMID: 17547586]">Smith 2007</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013575-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD013575-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-FIG-02" target="_blank"><b></b></a></p> </div><img alt=". Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013575-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p><a href="#CD013575-fig-0002">Figure 2</a>. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-FIG-03" target="_blank"><b></b></a></p> </div><img alt=". Risk of bias table" data-id="CD013575-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p><a href="#CD013575-fig-0003">Figure 3</a>. Risk of bias table </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 1: Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode)" data-id="CD013575-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 1: Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 2: Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode)" data-id="CD013575-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 2: Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 3: Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines)" data-id="CD013575-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 3: Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 4: Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short‐term)" data-id="CD013575-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 4: Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 5: Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term)" data-id="CD013575-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 5: Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 6: Adverse effects up to 12 weeks after starting treatment (short‐term)" data-id="CD013575-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 6: Adverse effects up to 12 weeks after starting treatment (short‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 7: Adverse effects 6‐12 months after initiating the intervention (long‐term)" data-id="CD013575-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 7: Adverse effects 6‐12 months after initiating the intervention (long‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 8: Recurrence of manic episode at one year" data-id="CD013575-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 8: Recurrence of manic episode at one year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lamotrigine versus placebo, Outcome 9: Recurrence of depressive episode at one year" data-id="CD013575-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Lamotrigine versus placebo, Outcome 9: Recurrence of depressive episode at one year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 1: Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode)" data-id="CD013575-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 1: Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 2: Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode)" data-id="CD013575-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 2: Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 3: Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines)" data-id="CD013575-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 3: Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 4: Recurrence of any episodes at one year (active suicidal behavior)" data-id="CD013575-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 4: Recurrence of any episodes at one year (active suicidal behavior) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 5: Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term)" data-id="CD013575-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 5: Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 6: Adverse effects 6‐12 months after initiating the intervention (long‐term)" data-id="CD013575-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 6: Adverse effects 6‐12 months after initiating the intervention (long‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 7: Recurrence of manic episode at one year" data-id="CD013575-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 7: Recurrence of manic episode at one year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013575-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/urn:x-wiley:14651858:media:CD013575:CD013575-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus lithium, Outcome 8: Recurrence of depressive episode at one year" data-id="CD013575-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_t/tCD013575-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus lithium, Outcome 8: Recurrence of depressive episode at one year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/media/CDSR/CD013575/image_n/nCD013575-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013575-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lamotrigine versus placebo for the maintenance treatment of bipolar disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine versus placebo in the maintenance treatment of bipolar disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> bipolar disorder<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (hospitalization for any episodes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Young Mania Rating Scale (YMRS) total score ≥15 for manic episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.51 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>663<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies reported that no recurrence of any episodes for one year Young Mania Rating Scale total score 15 or greater for manic episode was recorded in the lamotrigine and control groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/>(48 to 159) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥15 for depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥14 for depressive episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1606<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>438 per 1,000<br/>(340 to 536) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.70 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>756<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000<br/>(428 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (active suicidal behavior)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was measured in one study, but no numeric data were provided.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.70 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>195<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 7 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1,000<br/>(196 to 472) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.78 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>700<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 1,000<br/>(426 to 625) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects up to 12 weeks after starting treatment (short term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.81 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1138<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 9 10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1,000<br/>(208 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects 6‐12 months after initiating the intervention (long term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>756<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1,000<br/>(428 to 594) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of manic episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.66 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>574<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1,000<br/>(149 to 288) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of depressive episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.53 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>574<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1,000<br/>(225 to 374) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by the 36‐Item Short Form Health Survey</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total severity score from depression and mania symptom scores, such as HDRS and the YMRS </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0 to 0 ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Publication bias was not evaluated due to limited data. </p> <p><sup>2</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a> and <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>3</sup> Downgraded by one level. Only <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a> provided OR and 95% CI. </p> <p><sup>4</sup> Downgraded by one level for inconsistency (I<sup>2</sup>= 60%). </p> <p><sup>5</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a> had unclear to high risk of detection bias (blinding of outcome assessors). </p> <p><sup>6</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>, <a href="./references#CD013575-bbs2-0003" title="CalabreseJR , SuppesT , BowdenCL , SachsGS , SwannAC , McElroySL , et al, Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry2000;61(11):841-50. ">Calabrese 2000</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>7</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> was included with unclear risk of bias). </p> <p><sup>8</sup> Downgraded by one level. Only <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> provided OR and 95% CI. </p> <p><sup>9</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0002" title="CalabreseJR , BowdenCL , SachsGS , AscherJA , MonaghanE , RuddGD , Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry1999;60(2):79-88. CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA , et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. ">Calabrese 1999</a> and <a href="./references#CD013575-bbs2-0050" title="CalabreseJR , HuffmanRF , WhiteRL , EdwardsS , ThompsonTR , AscherJA ,  et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders2008;10(2):323-33. [PMID: 18271912]">Calabrese 2008</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> <p><sup>10</sup> Downgraded by two levels for very serious inconsistency (I<sup>2</sup>= 82%) </p> <p><sup>11</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a>, <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0009" title="KoyamaT , HiguchiT , YamawakiS , KanbaS , TeraoT , ShinoharaA . Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar Ⅰ disorder patients. Japanese Journal of Clinical Psychiatry2011;40:369-83. NCT00550407. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. clinicaltrials.gov/ct2/show/NCT00550407 (first received 27 July 2010). ">Koyama 2011</a> had unclear to high risk of detection bias (blinding of outcome assessment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lamotrigine versus placebo for the maintenance treatment of bipolar disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013575-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine versus lithium for the maintenance treatment of bipolar disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine versus lithium in the maintenance treatment of bipolar disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> bipolar disorder<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> lithium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lithium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (hospitalization for any episodes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Young Mania Rating Scale (YMRS) total score ≥15 for manic episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.57<br/>(0.15 to 85.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥15 for depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥14 for depressive episode) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.70 to 2.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/>(44 to 179) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.92 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1,000<br/>(380 to 543) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of any episodes at one year (active suicidal behavior)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.06 to 15.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>155<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000<br/>(1 to 176) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.88 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>636<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>663 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1,000<br/>(491 to 677) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects up to 12 weeks after starting treatment (short term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any reported adverse effects 6‐12 months after initiating the intervention (long term)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.51 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>691<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1,000<br/>(164 to 294) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of manic episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/>(1.32 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>206 per 1,000<br/>(136 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of depressive episode at one year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.63 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1,000<br/>(227 to 373) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by the 36‐Item Short Form Health Survey</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total severity score from depression and mania symptom scores, such as HDRS and the YMRS </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was not reported in any studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0011" title="SuppesT , MarangellLB , BernsteinIH , KellyDI , FischerEG , ZboyanHA , et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders2008;111(2-3):334-43. ">Suppes 2008a</a> was included). </p> <p><sup>2</sup> Downgraded by two levels due to wide CIs. </p> <p><sup>3</sup> Publication bias was not evaluated due to limited data. </p> <p><sup>4</sup> Downgraded by one level due to wide CIs. </p> <p><sup>5</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0001" title="BowdenCL , CalabreseJR , SachsG , YathamLN , AsgharSA , HomplandM , et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry2003;60(4):392-400. ">Bowden 2003</a> and <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> were judged to be at high risk of detection bias (blinding of outcome assessment). </p> <p><sup>6</sup> Downgraded by one level for risk of bias (only <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a> was included). </p> <p><sup>7</sup> Downgraded by one level for risk of bias. <a href="./references#CD013575-bbs2-0004" title="CalabreseJR , BowdenCL , SachsG , YathamLN , BehnkeK , MehtonenOP , et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry2003;64(9):1013-24. ">Calabrese 2003</a> and <a href="./references#CD013575-bbs2-0010" title="LichtRW , NielsenJN , GramLF , VestergaardP , BendzH . Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders2010;12(5):483-93. NCT00226135. Prophylactic effect of lamotrigine compared with lithium in bipolar disorder. clinicaltrials.gov/ct2/show/NCT00226135 (first received 26 September 2005). ">Licht 2010</a> were judged to be at high risk of detection bias (blinding of outcome assessment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine versus lithium for the maintenance treatment of bipolar disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/full#CD013575-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013575-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lamotrigine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.51, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Withdrawal from treatment due to any reason, up to 12 weeks after intervention commencement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.70, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse effects up to 12 weeks after starting treatment (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.81, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse effects 6‐12 months after initiating the intervention (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Recurrence of manic episode at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.66, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Recurrence of depressive episode at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.53, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lamotrigine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013575-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lamotrigine versus lithium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Recurrence of any episodes at one year (Young Mania Rating Scale total score ≥15 for manic episode) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [0.15, 85.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale total score ≥15 for depressive episode; Hamilton Depression Rating Scale total score ≥14 for depressive episode) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.70, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.92, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Recurrence of any episodes at one year (active suicidal behavior) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse effects 6‐12 months after initiating the intervention (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Recurrence of manic episode at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.32, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Recurrence of depressive episode at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lamotrigine versus lithium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013575.pub2/references#CD013575-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013575.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013575-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013575-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013575-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013575-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013575-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013575-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013575-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD013575-note-0006">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013575-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013575-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013575\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013575\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013575\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013575\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013575\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013575.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013575.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013575.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013575.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013575.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715292264"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013575.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715292268"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013575.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8389da72f446',t:'MTc0MDcxNTI5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 